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ABSTRACT aB-Crystallin is a small heat-shock protein (sHsp) that is colocalized with a-synuclein (aSyn) in Lewy bodies—the
pathological hallmarks of Parkinson’s disease—and is an inhibitor of aSyn amyloid ﬁbril formation in an ATP-independent
manner in vitro. We have investigated the mechanism underlying the inhibitory action of sHsps, and here we establish, by means
of a variety of biophysical techniques including immunogold labeling and nuclear magnetic resonance spectroscopy, that
aB-crystallin interacts with aSyn, binding along the length of mature amyloid ﬁbrils. By measurement of seeded ﬁbril elongation
kinetics, both in solution and on a surface using a quartz crystal microbalance, this binding is shown to strongly inhibit further
growth of the ﬁbrils. The binding is also demonstrated to shift the monomer-ﬁbril equilibrium in favor of dissociation. We believe
that this mechanism, by which a sHsp interacts with mature amyloid ﬁbrils, could represent an additional and potentially generic
means by which at least some chaperones protect against amyloid aggregation and limit the onset of misfolding diseases.
INTRODUCTION
Parkinson’s disease (PD) is a progressive neurodegenerative
movement disorder distinguished neuropathologically by the
presence of Lewy bodies and Lewy neurites—proteinaceous
cytoplasmic inclusions—in dopaminergic neurons of the
substantia nigra (1). Electron microscopy shows these inclu-
sions to be composed of amyloid-like ﬁbrillar material, the
major component of which is the 140-residue, intrinsically
disordered protein a-synuclein (aSyn) (2). Recombinant
aSyn has been found to form aggregates in vitro with all
the characteristics of amyloid ﬁbrils associated with diseased
states (3). Although most cases of PD are idiopathic, a small
number of familial forms have been identiﬁed including the
A53T variant, in which aggregation is signiﬁcantly acceler-
ated relative to the wild-type (WT) (4), thus implicating
aSyn aggregation in the etiology of PD. As aSyn knockout
mice do not exhibit PD-like symptoms, it can be concluded
that PD results from a pathological gain of function (i.e.,
aggregate toxicity) rather than the loss of normal aSyn
function (5).
The aggregation mechanism itself, in common with other
amyloid systems, is a nucleated process in which there is
slow and initially unfavorable association of monomers
into a structure competent to elongate into full-length ﬁbrils
(6). An important experimental consequence of such a nucle-
ation-polymerization mechanism is the phenomenon of seed-
ing, in which a substoichiometric quantity of preformed
ﬁbrils can greatly accelerate the aggregation reaction by by-
passing the nucleation process. The aggregation kinetics of
seeded reactions are therefore determined only by the elon-
gation and fragmentation rates, and, in the initial rate approx-
imation, by the elongation rate alone (7).
aSyn aggregation may be suppressed by the molecular
chaperoneHsp70,andbiophysicalinvestigationshaveshown
that this inhibition occurs via binding to preﬁbrillar species
rather than monomeric aSyn (8). Another molecular chap-
erone that inhibits aSyn aggregation is aB-crystallin, a
175-residue protein ubiquitous in mammalian tissue (9).
Early work showed that aB-crystallin is a member of the
family of small heat shock proteins (sHsps), and is upregu-
lated in response to a range of stress stimuli and clinical
disorders including Alzheimer’s disease, transmissible spon-
giform encephalopathies, dementia with Lewy bodies, and
Parkinson’sdisease(10).AsasHsp,aB-crystallinisamolec-
ular chaperone and has been demonstrated to suppress
thermally induced aggregation of b- and g-crystallins, sug-
gesting that it acts as a signiﬁcant protective mechanism
against cataract formation in the eye lens (11); the latter is
associated with aggregation and has been shown in some
cases to involve amyloid formation (12). aB-Crystallin
also inhibits the aggregation of several other proteins
in vitro, including the amyloid-b peptides, b2-microglobulin,
and insulin (13,14). There are, however, conﬂicting reports
as to whether such inhibition is neuroprotective (15,16).
The sequence of aB-crystallin has amphipathic character,
and contains a hydrophobic N-terminal domain, a central
a-crystallindomain(commontoallsHsps),andahydrophilic
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pathic nature of the sequence is believed to be crucial to its
chaperone function, enabling aB-crystallin to bind to
exposed hydrophobic patches characteristic of misfolded
states (17). The hydrophilic and highly ﬂexible C-terminal
extension, as characterized by solution state nuclear
magnetic resonance (NMR) (18), is also essential to efﬁcient
chaperone activity, with an important role in solubilizing
complexes of the chaperone with misfolded and aggregated
species (10). No crystal structure of aB-crystallin has yet
been determined;comparison of thea-crystallin domain with
structures of other sHsps, however, suggests that the central
domain will adopt a b-sandwich structure (19). A major
barrier to structural characterization of aB-crystallin, and
certainly to its crystallization, is the self-association of
monomers into large, polydispersed assemblies (typically
24–33mers), with molecular masses varying from 300 kDa
to >1 MDa (20). Studies of the quaternary structure of the
protein by cryo-electron microscopy reveal spherical assem-
blies between 8 and 18 nm in diameter with a central cavity
(21), which undergo subunit exchange on a timescale of
minutes (22). This exchange is inhibited by binding to large
denatured or partially unfolded proteins, suggesting that
subunit exchange may have an important role in the mecha-
nism of chaperone action (10,22).
aB-Crystallin accumulates in neurons and glia of the
central nervous system under pathological conditions (23),
becoming colocalized with aSyn in Lewy bodies along with
a host of other proteins including the sHsp Hsp27, and other
chaperones such as clusterin, Hsp70, and Hsp90 (24).
Invitrobiophysicalstudiesdemonstratedcompleteinhibition
of the nucleated assembly of aSyn into ﬁbrils by 0.25 equiv-
alents of aB-crystallin (25). Imaging studies of the aggrega-
tion products showed large amounts of amorphous material,
which was interpreted as the binding of aB-crystallin to
monomeric or oligomeric intermediates, inhibiting the nucle-
ation of ﬁbrillar aSyn aggregates. Later studies additionally
demonstrated that the addition of 0.5 equivalents of aB-crys-
tallintoaggregatingsamplesofaSynishighlyeffectiveinin-
hibiting further growth, and this was also interpreted as
aconsequenceofthestabilizationofmonomericorpreﬁbrillar
aSyn, inhibiting its incorporationinto the growing ﬁbril (26).
Given the complex mechanisms of amyloid formation and
thenumberofaggregatedspeciesinvolved—e.g.,monomers,
oligomers, protoﬁbrils, ﬁbrils, and amorphous assemblies—
we were motivated to consider the interaction of aB-crystal-
lin with additional species along the aggregation pathway
and, in particular, with the mature ﬁbrils themselves, which
hithertohavelargelybeenregardedasinertreactionproducts.
There is evidence, however, that this view might not be
correct, as aB-crystallin has been reported to bind to Ab40
ﬁbrils, and it has been suggested that this interaction may
inhibit further aggregation (13), although the experimental
data reported could not conclusively distinguish between
the effects of the chaperone in solution or bound to the ﬁbril.
A separate study of insulin aggregation at low pH demon-
strated that ﬁbril elongation is inhibited after the incubation
of the insulin ﬁbrils with aB-crystallin, where the detection
of binding stimulated the proposal that the latter serves to
limit further ﬁbril growth (14). Here we investigate the
hypothesis that aB-crystallin might bind to aSyn ﬁbrils,
and use a variety of techniques including newly developed
QCM and NMR methodologies to explore the range of
effects that result from such chaperone-ﬁbril interactions.
MATERIALS AND METHODS
These are described in the Supporting Material.
RESULTS
Characterization of aSyn interactions
with aB-crystallin
The cosedimentation of aB-crystallin and two control
proteins (green ﬂuorescent protein, GFP, and ubiquitin
hydrolase, UCH-L3) with preformed A53T aSyn ﬁbrils
was assayed by SDS-PAGE (Fig. 1 A). A53T aSyn was
chosen for this study because of its high aggregation propen-
sity relative to the WT protein (4), and it was found to pellet
aB-crystallin in a similar manner to that previously observed
for the WT (25). The intensity of staining with Coomassie
blue was used to estimate the amount of aB-crystallin
present in the pelleted fraction (Fig. S1 A in the Supporting
Material), and an approximate binding ratio of 0.6:1 aB-
crystallin:aSyn was determined, where the latter refers to
the concentration of the constituent monomers within the
ﬁbrils and the observed staining intensity was normalized
by protein mass. The corresponding binding ratios for GFP
and UCH-L3 were 0.1:1 and 0.01:1, respectively, both
consistent with residual material expected from the incom-
plete washing of the pellet, and indicating that the sedimen-
tation of aB-crystallin was not due to any generic afﬁnity of
proteins for hydrophobic patches on the ﬁbril surface, or
rheological effects from the ﬁbril network during centrifuga-
tion. aB-Crystallin alone was not observed to sediment
under these conditions (Fig. S1, B and C).
The intrinsic tryptophan ﬂuorescence of aB-crystallin was
used to estimate the concentration of the protein remaining in
solution after incubation with preformed A53T ﬁbrils and
centrifugation for 30 min at 16,000   g (Fig. 1 B); these
conditions were found sufﬁcient to pellet aSyn ﬁbrils
completely, and as aSyn does not contain any tryptophan
residues, it exhibits little intrinsic ﬂuorescence. Only a small
(6%) though reproducible enhancement of aB-crystallin
ﬂuorescence was detected in the presence of monomeric
aSyn (Fig. 1 B), with a concomitant blue-shift of 1 nm
(343–342 nm) indicative of the ﬂuorophore being in a
more hydrophobic environment, and consistent with the
existence of a weak interaction between aB-crystallin and
monomeric aSyn (25).
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aSyn further, aB-crystallin was titrated into uniformly
15N-labeled aSyn, and changes in the amide chemical shifts
were monitored by recording [
1H,
15N]-HSQC experiments
(Fig. S2). Few signiﬁcant changes were observed, and the
largest perturbation, at His
50, can be attributed to its high
sensitivity to small changes in pH, an observation noted
previously in titrations of monomeric aSyn (8). A small,
uniform increase in signal intensity was observed, in contrast
to previous reports of a uniform loss of intensity (25). This
ﬁnding suggests that these changes are more probably attrib-
utable to the effect of slight pH changes on amide exchange
broadening than to the association of aSyn and aB-crystal-
lin. Thus, whereas measurements of tryptophan ﬂuorescence
imply that some interaction exists between the proteins, the
NMR results reported both here and previously (25) together
suggest that this is only transient and of low afﬁnity, similar
perhaps to that characterized between aB-crystallin and the
amyloid-b peptide (27). For these reasons, these interactions
have not been explored further in this work.
The ﬂuorescence assay was then used to measure the
concentration of aB-crystallin remaining in solution after
precipitation by the addition of aSyn ﬁbrils at two concentra-
tions. A precise determination of the stoichiometry or afﬁnity
of the interaction between the sHsp and ﬁbrils is complicated
by the effect of the interaction of aSyn monomer with
aB-crystallin, as discussed above, and Rayleigh scattering
resulting from the small number of aSyn ﬁbrils that remain
in solution after centrifugation. In addition, allowance had
to be made for the effect of aB-crystallin on the monomer-
ﬁbril equilibrium (discussed later) and hence on the absolute
ﬁbril concentration. For these reasons, an exact analysis has
not been attempted, but it was observed that binding is
proportional to the ﬁbril concentration, and an approximate
ratio of 0.23 5 0.06 bound aB-crystallin monomers per
aSyn monomer was calculated. This value is expected to
be a lower bound, with an absolute uncertainty greater
than the quoted standard deviation of the observations,
because of the factors discussed above. It is, however, of a
comparable order of magnitude to that estimated by densi-
tometry (Fig. S1 A).
The binding ratios determined above may be restated in
terms of the available ﬁbril surface area, using a toy model
(described in Materials and Methods; see Supporting Mate-
rial) in which the aB-crystallin-ﬁbril interaction is approxi-
mated as hard spheres of aB-crystallin monomers packing
onto a cylindrical ﬁbril surface. Although there is evidence
that the active subunits of aB-crystallin may be dimeric
(28), provided that both monomers within any such dimers
interact with the ﬁbril surface, we expect that this simple
model of monomeric binding will remain approximately
applicable. Such an analysis determines an approximate
maximum binding ratio of 0.90 5 0.29 aB-crystallin mono-
mers per aSyn monomer, hence the values determined by
ﬂuorescence and densitometry correspond to surface cover-
ages of approximately 26 5 11% and 62 5 20%, respec-
tively. Such high values require that the chaperone must
bind to the overall surface of the aSyn ﬁbrils, and not just
to the small number of ﬁbril ends.
Inhibition of ﬁbril elongation observed
by in situ ThT ﬂuorescence
Previous studies have examined the effect of aB-crystallin
on the sigmoidal kinetics characteristic of nucleated poly-
merization (and fragmentation) reactions associated with
the conversion of aSyn into amyloid ﬁbrils (25,26). Such
reactions are typically highly stochastic, however, and their
quantitative interpretation in terms of individual microscopic
processes and rates is complex (7). To simplify the kinetic
analysis in this work, preformed ﬁbrils were used to seed
the aggregation reaction in order that the elongation step
alone could be examined. A series of seeded aggregation
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FIGURE 1 Characterization of interactions between aB-crystallin and
aSyn. (A) SDS-PAGE assay of the binding of aB-crystallin, GFP, and
UCH-L3 (all 50 mM) to aSyn ﬁbrils (70 mM), showing both soluble frac-
tions, S, and pelleted fractions, P, after centrifugation for 30 min at
16,000   g.( B) Intrinsic ﬂuorescence of solutions containing aB-crystallin
(35 mM) and/or aSyn monomer (35 mM). The spectrum of aSyn monomer
alone has also been subtracted from that of aB-crystallin þ aSyn to illustrate
the 6% enhancement of aB-crystallin ﬂuorescence observed in the presence
of aSyn ([aB þ aS] – aS). Additionally, a spectrum of aB-crystallin
remaining in solution after centrifugation with 0.5 equivalence of aSyn
ﬁbrils is presented (aB þ aSFib).
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sHsp Binding Inhibits Amyloid Elongation 845experiments were performed in which the initial elongation
velocities were determined as a function of the concentration
of aB-crystallin (Fig. 2 A). These data show clearly that ﬁbril
growth was inhibited at low micromolar concentrations of
aB-crystallin. Fitting to a sigmoidal dose-response curve
determined the IC50 (the concentration of aB-crystallin for
half-maximal inhibition) to be 335 5 86 nM, although
some dependence on the seed concentration may also be dis-
cerned, which shall be discussed later in this article.
To identify whether or not the inhibition observed above
resulted from the binding of chaperone to aSyn in ﬁbrils
or free in solution, ﬁbrils were preincubated with aB-crystal-
lin then pelleted, washed, resuspended, and used to seed
solutions of monomeric aSyn. Fig. 2 B plots the resultant
kinetic proﬁles, and shows that elongation of chaperone-
bound ﬁbrils was signiﬁcantly inhibited (~70-fold) relative
to untreated ﬁbrils, by analysis of the initial rates. The
residual concentration of aB-crystallin after pelleting and
washing was estimated to be %35 nM. This is an order-of-
magnitude below the IC50 and therefore not by itself sufﬁ-
cient to inhibit elongation, as indicated by the marker in
Fig. 2 A. We therefore conclude that the observed inhibition
of elongation results from the speciﬁc interaction of aB-
crystallin with the aSyn seed ﬁbrils.
Inhibition of ﬁbril elongation observed
with a quartz crystal microbalance
To verify the model of inhibition discussed above, an inde-
pendent technique utilizing a quartz crystal microbalance
(QCM) was employed. QCM is a technique in which the
mass deposited on the surface of a quartz crystal oscillator
may be determined directly via measurement of the
frequency of oscillation, and recently the method has been
applied to the study of amyloid growth by measuring the
change in mass of growing ﬁbrils attached to the surface
(14). Importantly, this technique enables us to examine the
elongation phase of ﬁbril growth in isolation to other
processes such as nucleation, and this has been used to deter-
mine the elongation kinetics of insulin ﬁbrils grown at low
pH, demonstrating the inhibition of their elongation by
aB-crystallin (14). In contrast to insulin ﬁbrils, aSyn ﬁbrils
did not adsorb directly onto the sensor surface, and instead
were covalently attached via lysine side chains, as described
in Materials and Methods (see Supporting Material). A
surface prepared in this manner is shown in Fig. 3 A, and
the ﬁbrils were observed to reproducibly elongate when
incubated with monomeric aSyn (Fig. 3 B). Elongation
was readily determined to be proportional to the monomer
concentration (Fig. S3), as previously observed by solution-
state measurements (6), implying that the presence of the sur-
face does not signiﬁcantly alter the elongation mechanism.
Fig. 3 C plots the change in deposited mass during a single
QCM experiment. This shows ﬁrstly the increase in mass
that results from the elongation of aSyn ﬁbrils in the pres-
ence of aSyn monomer (arrow 1). The subsequent injection
of aB-crystallin with aSyn monomer (arrow 2) resulted in
a large increase in mass indicative of a binding interaction.
After 10 min, the reaction chamber was washed thoroughly
with buffer to eliminate unbound chaperone, yet upon the
injection of fresh aSyn monomer (arrow 3), further elonga-
tion was inhibited approximately sevenfold. As no free
aB-crystallin remained in solution, inhibition must have
resulted from the persistent binding of the chaperone to
ﬁbrils, providing strong support for the solution-state inhibi-
tion results presented previously in Fig. 2.
A second experiment (Fig. 3 D) conﬁrmed this observa-
tion: on injection of aSyn and aB-crystallin, a large initial
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FIGURE 2 Effect of aB-crystallin on aSyn aggregation kinetics. (A)
Determination of the effective aB-crystallin concentration required for inhi-
bition of seeded ﬁbril elongation in the presence of 35 mM aSyn monomer,
as a function of varying ﬁbril mass, given as the % seed. Data were globally
ﬁtted to a one-site binding model as described in Materials and Methods (see
Supporting Material). Initial rates have been normalized to aSyn elongation
in the absence of aB-crystallin. The marker (*) indicates the relative
inhibition resulting from the preincubation of the ﬁbril seed with aB-crystal-
lin, observed in Fig. 2 B, given that the estimated residual concentration of
aB-crystallin was <35 nM. (B) Seeded elongation kinetics, monitored by
in situ ThT ﬂuorescence. Samples containing 70 mM aSyn ﬁbrils and/or
70 mM aB-crystallin, as indicated in the legend, were pelleted, washed,
and resuspended, then used to seed fresh aSyn monomer (35 mM, 5% w/w
seed, 20 mM ThT).
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846 Waudby et al.increase in mass loading was detected. In contrast to the
previous experiment, this binding was allowed to saturate,
and after ~30 min a small but constant elongation rate was
observed. It is perhaps noteworthy that this timescale for
association is of similar magnitude to that for the subunit
exchange of aB-crystallin (22), and may indicate that the
aB-crystallin subunits are the active chaperone species.
Again, the observed inhibition persisted when the reaction
chamber was ﬂushed with fresh buffer. After overnight incu-
bation of the crystallin-treated ﬁbrils in fresh buffer,
however, the ability of the ﬁbrils to elongate was partially
restored, thus demonstrating the reversibility of the ﬁbril-
crystallin interaction. But the results also imply that dissoci-
ation of the complex occurs only on a timescale of several
hours, which is suggestive of a tight binding interaction.
NMR investigations of the interaction
of aB-crystallin with aSyn ﬁbrils
Large species such as amyloid ﬁbrils, with masses of approx-
imately GDa, have traditionally been assumed to be beyond
the reach of solution-state NMR methods. Recent investiga-
tionshavedemonstrated,however,thatinsomecasesnoncore
regionsofﬁbrilshavesufﬁcientﬂexibilitytoallowustodetect
sharp resonances (29). Therefore, in a one-dimensional
1H
NMR spectrum of aB-crystallin in the presence of aSyn
ﬁbrils, there are four components that may potentially
be observed: ﬁbrillar aSyn; residual aSyn monomers;
monomeric/oligomeric aB-crystallin; and ﬁbril-bound aB-
crystallin. Residual monomeric species are key observables
in the study of the thermodynamics of polymerization, and
measurements designed to estimate this concentration have
been used to characterize the energetics of elongation for
several ﬁbril-forming systems (30). The
1H spectrum of
aB-crystallin has previously been characterized, and reveals
that in the native oligomeric complex, the ﬁnal 12 residues
in the C-terminal extension have sufﬁcient mobility to be
observable by solution-state NMR (18).
Before examination of the ﬁbril-chaperone complex, the
spectrum of aSyn ﬁbrils in solution was explored. Fig. 4 A
shows a portion of the one-dimensional
1H NMR spectrum
of a solution of aSyn ﬁbrils (green line). The ﬁbril spectrum
appears almost identical to that of monomeric aSyn (not
shown), albeit with signiﬁcantly reduced intensity. Although
this spectrum suggests that the bulk of the observed signal
arises from residual monomers in solution rather than the
ﬁbrils, a more detailed study was nevertheless carried out
using a series of pulsed-ﬁeld gradient (PFG) measurements
to deﬁne the effective diffusion coefﬁcient Deff of the species
giving rise to the resonances. For monomeric proteins, Deff
is identical to the translational diffusion coefﬁcient Dtrans,
and its value is independent of the diffusion delay in the
NMR experiment, D. By contrast, for very large molecular
assemblies such as amyloid ﬁbrils, Deff can include contribu-
tions from rotational diffusion such that Deff > Dtrans for
small values of D (31). Deff is shown in Fig. S4 as a function
of D for a solution containing aSyn ﬁbrils, and no such vari-
ation was detected. The mean value of Deff was 8.6(5 1.7)  
10
 11 m
2 s
 1, which is entirely consistent with that expected
for a small monomeric protein (32). Thus, in contrast to other
amyloid systems such as the SH3 dimer, for which ﬁbril
resonances are observable (29), the NMR signal in Fig. 4 A
may be attributed to residual aSyn monomers alone.
Having examined the spectrum of isolated aSyn ﬁbrils (in
equilibrium with residual monomer), it is then possible to
analyze their interaction with aB-crystallin. Fig. 4 A shows
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FIGURE 3 Measurement of ﬁbril elongation by QCM.
AFM imaging of the (A) preparation and (B) growth of
aSyn ﬁbrils on an activated gold surface. (C) The effect
of aB-crystallin on ﬁbril elongation, studied by QCM.
Mass loading plot showing mass changes calculated from
the (a) third, (b) ﬁfth, and (c) seventh harmonics of the
crystal. Arrows indicate injection of 1), 0.25 mg/mL
A53T; 2), 0.25 mg/mL A53T plus 0.18 mg/mL aB-crystal-
lin; and 3), 0.25 mg/mL A53T, showing approximately
sevenfold inhibition of elongation. (D) Elongation rates
determined in a separate QCM experiment, where aSyn
monomer was injected at 0.1 mg/mL in the absence or pres-
enceof aB-crystallinat 0.5 mg/mL,as labeled on the xaxis.
The reaction chamber was ﬂushed with fresh buffer
between measurements. As in Fig. 3 C, on injection of
aB-crystallin and aSyn, a large increase in mass loading
occurred over ~0.5 h, after which linear growth was
observed, and the elongation rate is plotted for this
steady-state condition. The ﬁnal measurement of elonga-
tion was performed after overnight incubation of the
surface in fresh buffer.
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1H NMR spectrum
of the ﬁbril-crystallin complex alongside spectra of each
component in isolation. Difference spectroscopy, normalized
using the internal DSS reference, reveals that the spectrum
of chaperone-bound ﬁbrils is not the sum of the original
components, but that there is additional signal in the spec-
trum of the complex. The difference spectrum had, however,
the same appearance as monomeric aSyn (Fig. 4 A). A com-
parison of intensities in repeated experiments using indepen-
dent ﬁbril samples determined that the mean aSyn intensity
in the presence of aB-crystallin is ~50% greater than that in
its absence.
Toinvestigatetheseresultsfurther,PFGNMRspectrawere
recorded to characterize the diffusion properties of the
observed resonances. To limit the contributions from rota-
tional motion to the diffusion coefﬁcients measured for
ﬁbril-associated species, a long (500-ms) diffusion period D
was employed (31). The effective diffusion coefﬁcients Deff
for each sample are plotted in Fig. 4 B and these data show
that the diffusion of aB-crystallin is retarded in the presence
of aSyn ﬁbrils, consistent with the formation of a ﬁbril-
chaperone complex. The measured diffusion coefﬁcients
correspond, according to the Stokes-Einstein relation, to
approximate hydrodynamic radii of 3.7 5 0.4 nm and 8.6 5
0.4 nm for free aSyn and aB-crystallin, respectively—in
good agreement with previous observations (21,33). The
effectivediffusioncoefﬁcientofaB-crystallininthepresence
of aSyn ﬁbrils corresponds, when modeled as rotating rigid
rods (31), to a mean ﬁbril length of 260 5 140 nm.
The simplest interpretation of these results is that the
C-terminal extension of aB-crystallin is not perturbed by
ﬁbril binding and remains free to tumble in solution; hence,
the one-dimensional NMR spectrum is not altered in the
presence of ﬁbrils. However, diffusion is retarded, a ﬁnding
consistent with the binding of aB-crystallin to the ﬁbrils. The
concentration of residual aSyn monomer is also increased in
the presence of aB-crystallin, indicating that the monomer-
ﬁbril equilibrium is perturbed by interactions with the chap-
erone. Although absolute concentrations of aSyn monomer
were not determined, the observed 50% increase in the
monomer concentration corresponds to a net destabilization
of 0.3 5 0.1 kcal mol
 1 in the free energy of ﬁbril elonga-
tion, assuming a simple polymerization model (30). It is
recognizable that the chaperone-monomer-ﬁbril system
comprises many coupled equilibria, and that there are poten-
tially multiple origins to the observed increase in monomer
concentration. It remains, however, a notable feature of poly-
merization reactions that a relatively small change in the net
elongation energy may still result in a large change in the
partition of monomers and ﬁbrils.
Imaging of the ﬁbril-chaperone complex
To conﬁrm the binding of aB-crystallin to aSyn ﬁbrils in
a more direct manner, immunoelectron microscopy was
employed to visualize the ﬁbril-crystallin complex. aSyn
ﬁbrils are of sufﬁcient size that their twisted ultrastructure
could be observed clearly in the electron microscope after
negative staining with uranyl acetate (Fig. 5 A). In contrast,
the aB-crystallin oligomers are more difﬁcult to distinguish,
particularlyinamulticomponentsystem.Sampleswerethere-
fore incubated with an antibody directed against aB-crystal-
lin, which was in turn stained with a secondary antibody
conjugated to 10-nm gold nanoparticles. Fig. 5 B shows a
sample of aB-crystallin prepared in this manner and nega-
tively stained with uranyl acetate; electron dense gold
nanoparticles are observed to be colocalized with the native
aB-crystallin assemblies. The aSyn ﬁbrils shown in Fig. 5 A
were also stained with the primary and secondary antibodies
by an identical protocol; no signiﬁcant nonspeciﬁc or back-
ground immunolabeling was observed. An immunolabeled
ﬁbril-crystallin complex containing 0.3 equivalents of aB-
crystallin was then imaged (Fig. 5 C), showing, very clearly,
the interaction of aB-crystallin along the length of the ﬁbrils,
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FIGURE 4 Interactionof aB-crystallinwith aSynﬁbrils observedby one-
dimensional
1H NMR spectroscopy. (A) Methyl and DSS (resonance at
0 ppm) regions of the one-dimensional
1H spectra of 70 mM A53T aSyn
ﬁbrils complexed with 20 mM aB-crystallin, and of the ﬁbrils and chaperone
separately. (B) Effective diffusion coefﬁcients determined for these samples
by PFG NMR experiments using a 500-ms diffusion delay.
Biophysical Journal 98(5) 843–851
848 Waudby et al.with gold nanoparticles observed on all faces of the ﬁbril
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DISCUSSION
The results of this article have enabled a novel mechanism to
be proposed for the inhibition of aSyn aggregation by the
small heat-shock protein aB-crystallin. aB-Crystallin has
been demonstrated to bind along the lateral surface of
aSyn amyloid ﬁbrils, and this interaction has been demon-
strated by a range of methods to inhibit elongation effec-
tively, with half-maximal inhibition at an aB-crystallin
concentration of 335 5 86 nM. Although the binding
epitopes of aB-crystallin and the ﬁbrils are unknown,
NMR investigations have determined that the C-terminal
extension of aB-crystallin is able to ﬂuctuate freely even
in the bound state, a ﬁnding consistent with its purported
role as a solubilizing domain (18). NMR measurements
also indicated that the presence of the chaperone perturbed
the monomer-ﬁbril equilibrium, consistent with a net desta-
bilization of the ﬁbrils by ~0.3 kcal mol
 1. This may indicate
that binding of aB-crystallin along aSyn ﬁbrils weakens the
interactions between adjacent aSyn molecules, similar to the
effect of coﬁlin binding to actin ﬁlaments (34), but the addi-
tional effect of a weak interaction between aB-crystallin and
monomeric aSyn cannot be ruled out at this stage.
In this work, a novel methodology based on QCM
measurements has been developed to monitor aSyn ﬁbril
elongation, in isolation from other processes such as nucle-
ation, and without the need for added probe molecules. As
has been demonstrated in studies of insulin aggregation
(14), this technique offers signiﬁcant promise for the quanti-
tative investigation of the kinetics and mechanism of aSyn
ﬁbril elongation. To apply this, however, methods were
developed similar to those used in surface plasmon reso-
nance to enable the gold surface to bind the ﬁbrils. This
approach is likely to be applicable to QCM measurements
of other amyloid systems that do not contain accessible thiols
or disulphides.
aB-Crystallin has previously been reported to inhibit
aSyn aggregation, when added even at the midpoint of
sigmoidal assembly curves, and it was hypothesized that
the chaperone acts by stabilizing monomeric or preﬁbrillar
species (25,26). The mechanism put forward in this study,
by which aB-crystallin could inhibit ﬁbril formation by
binding to the ﬁbrils and inhibiting their elongation, suggests
that there may be multiple mechanisms of chaperone action.
As binding is likely to occur at least in part to the hydro-
phobic clusters that may form in the ﬁbrils, it is likely that
aB-crystallin will also interact strongly with the oligomeric
precursor species, an important property given their cyto-
toxic nature (2).
Two mechanisms can be envisaged to rationalize the inhi-
bition of elongation that results from the interaction of aSyn
ﬁbrils with aB-crystallin: one is a speciﬁc capping interac-
tion of aB-crystallin with the ﬁbril ends, assuming that the
binding here is tighter than that along the length of the ﬁbril;
and the second involves uniform binding of aB-crystallin
along the length of the ﬁbril, where inhibition results from
the chance occlusion of the ﬁbril ends. In this latter binding
and occlusion model, inhibition is expected to be observed
only in the presence of near equimolar ratios of aB-crystallin
and aSyn ﬁbrils, and the dependence of the IC50 upon the
seed concentration noted in Fig. 2 A would be consistent
with such a mechanism. Further investigations of the stoichi-
ometry and afﬁnity of the ﬁbril-chaperone interaction will,
however, be required to differentiate these models with
conﬁdence.
A key question in the study of sHsps is whether the native
oligomers act as chaperones directly, or whether dissociation
into subunits occurs before their binding (35). The approxi-
mate binding ratios presented in this work would be consis-
tent with either a relatively uniform binding of monomeric or
dimeric aB-crystallin subunits along the ﬁbril surfaces, or a
rarer binding of the oligomers. The high surface coverage
that would result from the subunit binding appears attractive
as a means of explaining the efﬁcacy of inhibition, particu-
larly as this effect persists when the chaperone is removed
from the solution after binding has occurred. Although this
mechanism of inhibition has not been put forward previ-
ously, it is consistent with previous studies in which sHsp
subunit exchange dynamics have been correlated to chap-
erone activity, in both aB-crystallin and its phosphorylated
derivatives (22,36).
These ﬁndings present the suggestion that other sHsps
may act by a similar mechanism. The Hsp20 from the bovine
parasite Babesia bovis inhibits Ab40 amyloid formation,
and the chaperone was active only at low (10–100 nM)
concentrations in which dimeric subunits were prevalent,
whereas at higher chaperone concentrations, in which larger
A B C FIGURE 5 Immunoelectron micros-
copy of aB-crystallin-aSyn ﬁbril com-
plexes. aB-Crystallin was labeled with
10-nm gold nanoparticles (arrows)a s
described in Materials and Methods
(see Supporting Material). (A) aSyn
ﬁbrils alone; (B) aB-crystallin alone;
and (C) aSyn ﬁbrils plus 0.3 equiva-
lence of aB-crystallin. All scale bars
are 500 nm.
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wasnolongerobserved(37).Additionally,aB-crystallinmay
bind to components of the cytoskeleton including inter-
mediate ﬁlaments and microtubules, although electron
microscopy has demonstrated that such binding occurs via
the oligomeric complex rather than isolated subunits (38).
This suggests that different chaperone activities (e.g., sup-
pressing amyloid formation, thermally induced amorphous
aggregation,andcytoskeletalbinding)correspondtoavariety
of phosphorylation or oligomerization states and binding
modes. For example, lysozyme unfolding intermediates are
bound by multimeric Hsp27 (39), and whereas aB-crystallin
activity against aSyn amyloid formation increases with
temperature (correlating with increased subunit exchange),
little variation with temperature was observed against the
thermally induced amorphous aggregation of alcohol dehy-
drogenase and citrate synthase (40). Phosphorylation-
mimicking mutations have also been demonstrated to differ-
entially regulate the chaperone activity of aB-crystallin
against amyloid ﬁbril formation and amorphous aggregation
(36). Equally, however, some of this variation may result
from a degree of speciﬁcity of individual members of the
sHsp family (41).
aB-Crystallin has shown no evidence of ATPase or
refolding activity (19). Instead, sHsps have been proposed
to bind to misfolded states before interaction with other
chaperone systems, which may facilitate refolding or degra-
dation (41). Horwitz et al. (9) has suggested that aB-crystal-
lin in the eye lens may act as an irreversible sink for unfolded
or misfolded proteins, as there is no evidence of further chap-
erone systems within the lens, and active protein synthesis
does not occur once the lens proteins are laid down. The
binding of aB-crystallin to aSyn ﬁbrils may therefore be a
protective mechanism to stem the growth of amyloid
deposits before clearance by further quality control mecha-
nisms within the cell (41). This hypothesis is supported
by a mouse model of PD expressing A53T aSyn, in which
selective upregulation of aB-crystallin was observed in
affected glial cells (42). Additionally, we suggest that
binding of aB-crystallin to ﬁbrils may reduce their cytotox-
icity by camouﬂaging exposed hydrophobic surfaces. This
hypothesis is supported by a tissue culture model of Lewy
body disease in which colocalization of aB-crystallin with
aSyn deposits occurs without a reduction in the number of
inclusions compared to cells not transfected with aB-crystal-
lin, although there is a signiﬁcant reduction in cytotoxicity
(43). Finally, as exposed ﬁbril surfaces have been proposed
to act as sites of secondary ﬁbril nucleation (44), the coating
of aSyn ﬁbrils by aB-crystallin could inhibit not just their
elongation but further nucleation processes as well. It is
also possible, however, that ﬁbril binding by chaperones
may have a deleterious role by sequestering them and
reducing their efﬁcacy in other physiological functions,
e.g., interacting with misfolded monomers or oligomers,
or, indeed, helping in regulation of the cytoskeleton (41).
Certainly, these ﬁndings reveal novel activities of the cellular
proteostasis network, which is of growing interest in the
ﬁeld of systems biology, and an increasing understanding
of its behavior may contribute to the rational development
of therapeutic proteostasis regulators (45).
This ﬁnding is also likely to have general relevance to
other amyloid and chaperone systems. Indeed, recent work
suggests that another chaperone, Hsp104, is capable of sup-
pressing amyloid growth at many stages along the aggrega-
tion pathway, including the elongation of mature ﬁbrils (46).
Fibril binding and inhibition of elongation by aB-crystallin
has previously been demonstrated for the Ab40 peptide,
although no causal link was demonstrated (13). Inhibition
of b2-microglobulin elongation by aB-crystallin at low pH
was also reported (13), and inhibition of insulin aggrega-
tion under similar conditions has also been observed (14).
This work is therefore important in extending mechanistic
studies of aB-crystallin to physiological conditions and,
given apparent similarities in the behavior of aSyn, Ab40,
b2-microglobulin, and insulin, suggests a generic mechanism
of aB-crystallin action.
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